CONTRIBUTIONS FROM THE MEMBER SOCIETIES. RE-EVALUATION OF PALIVIZUMAB USAGE IN ISRAEL

CONTRIBUTION

INTERNATIONAL COLLABORATIONS TO SCIENTIFIC REASEARCH IN PEDIATRICS, HIGHLIGHTS FROM THE 7th EUROPAEDIATRICS CONGRESS IN FLORENCE: THE PAST-PRESIDENT RUBINO’S WELLCOME ADDRESS, ...

CONTRIBUTIONS FROM THE MEMBER SOCIETIES RE-EVALUATION OF PALIVIZUMAB USAGE IN ISRAEL The new recommendations of the American Academy of Pediatrics (AAP) calling for a more limited and narrower usage of palivzumab (synagis) for the prevention of RSV in high risk groups have caused some confusion among pediatricians in Israel. <...> For the last decade several professional associations in Israel especially the Neonatology and The Pediatric Pulmonology Associations have advocated for a gradual expansion of the populations eligible for this expensive technology. <...> While 14 years ago synagis was recommended for 200 infants born than 28 weeks and those with chronic lung diseases, the funding for the prophylaxis was consistently increased and recently includes all infants born 34 week + 7 days and included 2750 eligible infants. <...> In response to this reaction, The Israeli Pediatric As sociation, has nominated an ad hoc committee that included the chairmen of the relevant associations and societies (Neonatology, Pediatric Pulmonology, Pediatric Intensive Care, Public Health, Pediatric Infectious Diseases, and representative of the Ministry of Health (MOH). <...> Palivizumab has been proven effective in reducing hospitalizations following RSV infection at high risk groups. 2. <...> Palivizumab has not been proven to reduce mortality associated with RSV infection. 3. <...> While palivizumab prophylaxis reduces ICU hospitalizations due to RSV infections, it was not shown to reduce mechanical ventilation due to this infection. 4. <...> The cost of prevention of 1 RSV hospitalization is different among different countries and could be quite high ( 250,000$ in most models). 5. <...> Palivizumab prophylaxis may decrease wheezing episodes among treated infants. 6. <...> While palivizumab may reduce hospitalizations among high risk patients its usage is not supposed to significantly affect the total burden of RSV infection since the overwhelming part of RSV hospitalization affect otherwise healthy infants who are not eligible for RSV prophylaxis. <...> To continue during the present winter (2014–2015 season) with the same criteria. 2. <...> To establish immediately following the present winter a cost benefit analysis in order to determine whether the current criteria are cost effective. <...> The analysis is supposed to be finished prior to the next season in order to define more correctly the population that is eligible <...>

• Похожие документы из РУАЭСТ
• |
• Похожие документы из Руконт